NCT04188639

Emicizumab in Acquired Hemophilia A

Emicizumab in Patients With Acquired Hemophilia A: Multicenter, Single-arm, Open-label Clinical Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: GWT-TUD GmbH · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an international, multicenter, open-label, single arm, prospective clinical trial and will evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).

Conditions

• Hemophilia A, Acquired

Interventions

Type	Name	Description
DRUG	Emicizumab Injection	All eligible patients with AHA will receive the same study medication consisting of once weekly subcutaneous emicizumab. For each subject, the maximal duration of the study will be 24 weeks including 12 weeks treatment with emicizumab and 12 weeks follow-up with Immunosuppressive therapy (IST) at the investigators discretion.

Timeline

• Start date: 2021-03-23
• Primary completion: 2023-01-04
• Completion: 2023-01-04
• First posted: 2019-12-06
• Last updated: 2023-01-09

Locations

16 sites across 2 countries: Austria, Germany